Sorrento Therapeutics Announces $25 Million Registered Direct Offering

October 7, 2019 sandiegobiotech News Comments Off on Sorrento Therapeutics Announces $25 Million Registered Direct Offering
Sorrento Therapeutics Announces $25 Million Registered Direct Offering
/

SAN DIEGO, Oct. 07, 2019 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, ?Sorrento?), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases, today announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase in a registered direct offering of 10,869,566 shares of its common stock and warrants to purchase up to 10,869,566 shares of its common stock, at a combined purchase price of $2.30 per share and related warrant. The offering is expected to close on or about October 9, 2019, subject to the satisfaction of customary closing conditions.

Related Articles

No Picture
News

Sorrento Publishes an Abivertinib Teaser Entitled “Abivertinib – A Franchise Oral Therapeutic for Cancer, COVID-19 and Autoimmune Diseases”

November 29, 2021 sandiegobiotech News Comments Off on Sorrento Publishes an Abivertinib Teaser Entitled “Abivertinib – A Franchise Oral Therapeutic for Cancer, COVID-19 and Autoimmune Diseases”

SAN DIEGO, Nov. 29, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced the publication of a Teaser titled “Abivertinib – a Franchise Oral Therapeutic for Cancer, COVID-19 and Autoimmune Diseases” (“Abivertinib Teaser”). Sorrento intends to use the Abivertinib Teaser to engage in discussions with interested third… Click here to view original post… […]

No Picture
News

Sorrento Receives FDA Clearance to Proceed With Clinical Trial for Anti-TROP-2 Antibody Drug Conjugate (TROP-2 ADC) for multiple solid tumors

October 13, 2021 sandiegobiotech News Comments Off on Sorrento Receives FDA Clearance to Proceed With Clinical Trial for Anti-TROP-2 Antibody Drug Conjugate (TROP-2 ADC) for multiple solid tumors

SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) previously announced that its partner Escugen Biotechnology Co, Ltd. (“Escugen”) and Sorrento’s subsidiary Levena (Suzhou) Biopharma Co., Ltd. (“Levena”) had received an approval letter from the Center for Drug Evaluation (CDE) of the National Medical… Click here to view original post… […]

No Picture
News

Dr. Henry Ji to Participate in Multiple Investment Conferences in September 2019 to Provide Corporate Updates

September 5, 2019 sandiegobiotech News Comments Off on Dr. Henry Ji to Participate in Multiple Investment Conferences in September 2019 to Provide Corporate Updates

SAN DIEGO, Sept. 05, 2019 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”), announced today that Dr. Henry Ji, Chairman and CEO, will participate in multiple investment conferences in September 2019. Dr. Ji will provide corp… […]